Calming Pet Treats: A Gentle Solution for Anxious Pets
These treats are specially formulated with natural ingredients to help pets relax without making them drowsy or lethargic. If you're looking for a way to ease your furry friend's anxiety, understanding the benefits and uses of calming treats can be a game-changer.
Calming pet treats are soft chews, biscuits, or snacks infused with ingredients that support relaxation and emotional balance. These treats are typically made with a blend of herbal extracts, vitamins, amino acids, and sometimes CBD (Cannabidiol) derived from hemp. They are completely safe for regular use and are designed to help pets stay calm during stressful situations.
Most calming treats are crafted using a blend of natural ingredients known to have soothing effects on the nervous system. Some of the most common ingredients include: Chamomile : A well-known herb for its calming and anti-inflammatory properties.
: A well-known herb for its calming and anti-inflammatory properties. Valerian Root : Often used in human supplements, it promotes calmness without causing sedation.
: Often used in human supplements, it promotes calmness without causing sedation. L-Theanine and L-Tryptophan : These amino acids help boost serotonin levels, encouraging a peaceful mood.
: These amino acids help boost serotonin levels, encouraging a peaceful mood. CBD or Hemp Oil : Offers relaxation and reduces nervous behavior without any psychoactive effects.
: Offers relaxation and reduces nervous behavior without any psychoactive effects. Melatonin: A hormone that helps regulate sleep and calm anxious behavior, especially during the night.
These ingredients work together to provide relief from anxiety, stress, hyperactivity, and aggression in both dogs and cats.
Calming treats can be used in various situations where your pet might feel nervous or unsettled. Some of the most common scenarios include: During fireworks or thunderstorms
Long car rides or air travel
Visits to the vet or groomer
Separation anxiety when left alone
New environments or changes in routine
Introducing new pets or people into the home
Administering calming treats 30–60 minutes before the stressful event can help ease your pet into a more relaxed state. Non-prescription and natural: Most calming treats are made with natural ingredients and do not require a prescription. Easy to administer: Unlike capsules or syrups, calming treats are tasty and often seen as rewards by pets. No major side effects: When given in proper amounts, these treats rarely cause adverse effects. Support for training: Calm pets are easier to train and more responsive to commands. Improved well-being: Reduced anxiety can lead to a happier, healthier, and more balanced pet.
Not all calming treats are created equal. It's important to select a reputable brand that uses high-quality, tested ingredients. Look for transparency in labeling, dosage instructions, and customer reviews. Trusted companies like HighV offer reliable options that prioritize your pet's health and well-being.
If you're considering adding calming pet treats to your pet care routine, always consult your veterinarian, especially if your pet has underlying health issues or is on medication.
Most calming treats begin to take effect within 30 minutes to an hour after consumption. However, the exact time may vary depending on the size, weight, metabolism, and stress level of your pet. For best results, administer the treats before a known stressor occurs and observe how your pet responds.
Yes, most calming treats are designed for both short-term and long-term use. They can be used daily for pets who suffer from chronic anxiety or on an as-needed basis during specific stressful events. However, it's crucial to follow the recommended dosage guidelines and seek advice from your vet if you're using them regularly.
Your pet's mental and emotional health is just as important as their physical health. Providing a calming environment and the right supplements can go a long way in ensuring their comfort and happiness. Calming pet treats are an easy, natural, and effective solution for managing anxiety in pets.
If you're looking for a trustworthy place to buy high-quality calming treats, consider visiting HighV's online store to explore a variety of calming solutions tailored to your pet's specific needs.
A relaxed pet is a happy pet—and with the right calming treats, you can help your furry companion face the world with confidence and calm.
TIME BUSINESS NEWS
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
5 days ago
- Associated Press
Prolon L-Protein Bar Sets New Standard for Clean, Age-Supportive Nutrition
L-Nutra's newest innovation is a plant-based protein bar formulated to support muscle health and slow age-related nutritional triggers, not just fuel fitness L-Nutra, a global leader in nutrition technology and longevity science, is once again redefining what precision nutrition can do with the launch of the Prolon® L-Protein Bar — a clean, plant-based bar scientifically formulated to provide the perfect balance of amino acids from plant-based sources to support both muscle health and healthy aging, not just workouts. Most protein products today are focused on quantity — more grams, more calories, more bulk. But emerging longevity science shows that too much of the wrong kind of protein can accelerate aging by overstimulating key growth pathways like IGF-1 and mTOR. On the other hand, too little protein — especially in strict vegan diets — may fail to adequately support muscle maintenance and overall strength. Achieving this balance is critical: while excessive protein, particularly from animal sources, may overstimulate pro-aging pathways, too little protein can undermine strength, energy, and overall resilience. The L-Protein Bar is carefully designed to navigate this middle path — delivering the right nutrients, in the right amounts, from the right sources. Now part of the Prolon suite of clinically informed nutrition tools, the L-Protein Bar continues L-Nutra's mission to create smarter everyday nutrition solutions rooted in more than two decades of research. 'If you want to live a long and healthy life, you need to slow the rate of aging every day — and that starts with what you eat,' says Dr. Joseph Antoun, a Harvard- and Johns Hopkins-trained physician and CEO of L-Nutra. 'Protein can accelerate aging if you're choosing the wrong types or the wrong amounts. Our novel L-Protein Bar, rooted in more than 25 years of longevity science, strikes the optimal balance: enough to support muscle strength, but not so much that it speeds up the aging process. And unlike most protein products, there are no hidden ingredients. We pride ourselves on quality ingredients and transparency in how we make our products.' A Protein Bar Built for the Future of Health Formulated by scientists at the USC Longevity Institute, the Prolon L-Protein Bar includes a diverse blend of plant-based proteins (from black beans, chickpeas, and peas) and is fortified with L-methionine, an essential amino acid typically low or missing in vegan diets and other vegan protein supplements. This targeted formulation is designed to maintain a balanced growth factor response while delivering complete protein support for muscle and tissue health. Each bar contains 14 grams of protein, only 170 calories, and is made without added sugars, sugar alcohols, or artificial sweeteners. Instead, it's naturally sweetened with whole dates for a rich flavor and more balanced glycemic response. How Our Protein Bar Redefines the Standard The bar launches in its first flavor, Chocolate Coated, featuring a 100% dark chocolate layer and a rich, satisfying taste. Additional flavors are planned as part of Prolon's expanding Longevity Nutrition platform — a product suite designed to help people integrate clinically-backed, health-supportive nutrition into daily life. The Prolon L-Protein Bar is now available for purchase at About L-Nutra L-Nutra is the global leader in nutri-technology, advancing the discovery, design, and delivery of clinically tested Nutrition for Longevity and Nutrition as Medicine programs. With over 134 issued patents and more than 47 published clinical studies in collaboration with 18 leading universities, L-Nutra's innovations harness the power of plant-based nutrition to support healthy aging, metabolic reset, and cellular rejuvenation. Through its consumer division, Prolon, L-Nutra offers a suite of fasting and longevity-focused products designed to reduce biological age and support whole-body wellness. Its medical division, L-Nutra Health, delivers clinically backed programs aimed at supporting the remission and regression of chronic conditions like type 2 diabetes and metabolic conditions through food-led, lifestyle medicine interventions. Together, these branches reflect L-Nutra's mission to transform what's possible through nutrition and longevity science. To learn more, visit Media Contact Melanie Murphy Richter [email protected] ### SOURCE: L-Nutra Copyright 2025 EZ Newswire
Business Upturn
06-08-2025
- Business Upturn
Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment
Presented data highlights the potential of Annamycin for treating broad range of human cancers, including high-need oncology indications Annamycin currently in late-stage clinical development in combination with cytarabine for the treatment of AML; Anticipated preliminary data readout in 2H 2025 HOUSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc., (Nasdaq: MBRX) ('Moleculin' or the 'Company'), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced the presentation of encouraging preclinical data for its lead drug candidate, Annamycin, also known by its non-proprietary name of naxtarubicin, which demonstrated significant efficacy against various primary and metastatic liver cancers, including hepatocellular carcinoma (HCC), colorectal liver metastases, and pancreatic ductal adenocarcinoma (PDAC) liver metastases. This is believed to be the result of targeted accumulation in the liver and other organs. These findings were highlighted in a poster titled ' Liposomal Annamycin (L-ANN) Efficacy Against Primary and Metastatic Liver Cancers , ' presented by Dr. Waldemar Priebe, Lead Author and Chairman of the Scientific Advisory Board at Moleculin at the recently held Shelby-Lavine Pancreatic Cancer Symposium at MD Anderson Cancer Center. Key Highlights Targeted Accumulation in Organs: The preclinical studies confirmed that Annamycin exhibits distinct organotropic properties, leading to significantly higher concentrations in the liver, spleen, lungs, and pancreas when compared to doxorubicin (DOX). This targeted accumulation is critical for effectively treating liver-localized tumors. The preclinical studies confirmed that Annamycin exhibits distinct organotropic properties, leading to significantly higher concentrations in the liver, spleen, lungs, and pancreas when compared to doxorubicin (DOX). This targeted accumulation is critical for effectively treating liver-localized tumors. Efficacy in Orthotopic Hepatocellular Carcinoma (HCC) Models: Annamycin demonstrated excellent anti-tumor activity in orthotopic HCC models (Hepa 1-6 Luc), showing a marked reduction in tumor progression and improved survival rates in treated animals compared to vehicle controls. Annamycin demonstrated excellent anti-tumor activity in orthotopic HCC models (Hepa 1-6 Luc), showing a marked reduction in tumor progression and improved survival rates in treated animals compared to vehicle controls. Potent Impact on Colorectal Liver Metastasis: In an experimental liver metastatic model of colorectal carcinoma (CT26 Luc), Annamycin significantly inhibited metastatic growth and extended survival, highlighting its potential for addressing liver metastases in colon cancer that affects close to 50% of patients. In an experimental liver metastatic model of colorectal carcinoma (CT26 Luc), Annamycin significantly inhibited metastatic growth and extended survival, highlighting its potential for addressing liver metastases in colon cancer that affects close to 50% of patients. Promising Results in Pancreatic Cancer Liver Metastasis: Annamycin also showed compelling efficacy in liver-implanted human pancreatic ductal adenocarcinoma (MIA PaCa-2), leading to inhibition of tumor growth, suggesting its potential role in managing advanced pancreatic cancer with liver involvement. Annamycin also showed compelling efficacy in liver-implanted human pancreatic ductal adenocarcinoma (MIA PaCa-2), leading to inhibition of tumor growth, suggesting its potential role in managing advanced pancreatic cancer with liver involvement. Favorable Safety Profile: Consistent with previous preclinical and clinical findings, Annamycin continued to show low or no cardiotoxicity, a significant advantage over traditional anthracyclines like doxorubicin, which are often limited by dose-dependent cardiac side effects. This safety profile was previously observed in clinical trials, where 32 out of 42 subjects reviewed received more than the FDA-established lifetime maximum allowable level of anthracycline without evidence of cardiotoxicity. 'We are incredibly encouraged by these preclinical results, which further validate Annamycin's potential as a powerful and differentiated therapeutic agent for liver cancers,' said Dr. Priebe. 'The ability of Annamycin to concentrate effectively in the liver, combined with its demonstrated efficacy across multiple aggressive liver cancer models and its favorable cardiotoxicity profile, positions it as a highly promising candidate for patients facing these devastating diseases. We believe these data provide a strong foundation for advancing Annamycin in clinical development for these indications, offering new hope where treatment options are often limited.' Walter Klemp, Chairman and CEO of Moleculin, added, 'We continue to be strongly encouraged by the potential of Annamycin. Beyond our preliminary programs in AML and soft tissue sarcoma lung metastases (STS lung mets), we continue to advance and develop Annamycin through multiple investigator-initiated studies to further unlock its potential as a treatment option for many other types of cancers. We believe this preclinical data highlights that potential and provides additional validation of its unique pharmacological profile and importantly showcases the opportunity for its use across a wide range of cancers.' Moleculin's novel drug candidate is being positioned to become the first ever non-cardiotoxic anthracycline to be approved and is currently being developed for the treatment of AML and STS lung mets. For more information, please visit About Moleculin Biotech, Inc. Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company's lead program, Annamycin, is a next-generation highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. The Company has begun the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents. Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications. For more information about the Company, please visit and connect on X, LinkedIn and Facebook. Forward-Looking Statements Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the whether the preclinical results described above are able to be reproduced in clinical trials. Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company's ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin has attempted to identify forward-looking statements by terminology including 'believes,' 'estimates,' 'anticipates,' 'expects,' 'plans,' 'projects,' 'intends,' 'potential,' 'may,' 'could,' 'might,' 'will,' 'should,' 'approximately' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. 'Risk Factors' in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. Investor Contact:JTC Team, LLCJenene Thomas(908) 824-0775 [email protected]
Yahoo
31-07-2025
- Yahoo
Ultromics Lands $55M Series C to Tackle Undiagnosed Heart Failure at Scale
AI heart failure diagnostics innovator makes it possible to catch deadly heart failure earlier by analyzing the most common heart scan in the world and proactively alerting clinicians FDA-cleared, reimbursed by Medicare, and live in top U.S. hospitals, Ultromics is now scaling nationwide to make early heart failure detection part of routine cardiac care, wherever patients get an echo Ultromics is trained on one of the largest real-world echo datasets globally and validated across 25 peer-reviewed studies, helping close one of medicine's most dangerous diagnostic gaps, where up to 64% of heart failure cases still go undetected OXFORD, England, July 31, 2025 /PRNewswire/ -- Ultromics, a pioneer in AI-driven cardiology solutions, today announced it has raised $55 million in Series C financing. The round was co-led by L&G, Allegis Capital and Lightrock, with continued support from Oxford Science Enterprises, GV, Blue Venture Fund and Oxford University. Major U.S. health systems, including UChicago Medicine's venture investment vehicle, UCM Ventures, and UPMC Enterprises also participated in the round. Built on years of clinical study and hundreds of thousands of echo scans, Ultromics offers the first FDA-cleared, Medicare-reimbursed AI technology to help clinicians detect HFpEF and cardiac amyloidosis, two of the most elusive forms of heart failure. The company is now expanding across the U.S. to bring that capability to the hospitals and echo labs that see the highest volume of at-risk patients, aiming to make AI-enhanced diagnostics a default step in the cardiac workup. Ultromics is also expanding its pipeline to include additional cardiac conditions, new distribution channels and deeper partnerships with health systems and clinical leaders. It's a critical moment for cardiovascular care. Heart failure is rising, costs are mounting and millions of patients are still going undiagnosed, especially those with harder-to-detect forms like HFpEF and cardiac amyloidosis. In the U.S. alone, heart failure drives over $30 billion in annual healthcare costs, a number projected to exceed $70 billion by 2030. Clinicians often rely on subjective interpretation of echocardiograms, leading to missed or delayed diagnoses even when patients are actively seeking care. In fact, up to 64% of HFpEF cases go undiagnosed, and cardiac amyloidosis is frequently mistaken for more common forms of heart disease, leaving patients untreated until symptoms worsen or irreversible damage occurs. Ultromics addresses this diagnostic blind spot by using AI to extract hidden disease signals from standard echocardiograms, enabling earlier, more accurate detection of complex heart conditions—without requiring new hardware or disrupting clinical workflows. Its FDA-cleared EchoGo® platform supports diagnosis of HFpEF and cardiac amyloidosis. Trained and validated on one of the largest real-world echo datasets globally, EchoGo® generates real-time probability scores to help cardiologists identify high-risk patients earlier than traditional methods. EchoGo® is fully reimbursed under Medicare, making it scalable across hospitals, clinics, and health systems nationwide. "The reality is, hospitals already have the data, they just haven't had the tools to extract the more subtle diagnostic signals from it. By analyzing routine echocardiograms with AI, we're helping clinicians identify high-risk patients earlier, enabling intervention before disease progresses," said Ross Upton, PhD, CEO and Founder, Ultromics. "We've spent years building our platform to fit into clinical workflows, with no extra hardware and no new friction, and this funding helps us scale that across the U.S. at a moment when health systems are actively looking to combat the growing heart failure crisis." Ultromics has already analyzed more than 430,000 echocardiograms to date. In clinical studies, EchoGo® improved the detection of HFpEF by 73.6% when compared with standard clinical risk scores. The company's latest diagnostic model for cardiac amyloidosis, validated in a global study of 18 institutions and published in the European Heart Journal, outperformed current clinical risk scores while distinguishing disease from similar conditions. "Ultromics has established itself as an early-mover in the large and underserved cardiovascular disease market, having developed one of the first commercially available AI-powered diagnostic echocardiogram technologies," said Alastair Stewart, Head of Investments, Venture Capital, at L&G. "This successful Series C round is a testament to the massive opportunity for cutting-edge technology to transform how clinicians can detect and treat serious cardiovascular diseases that impact millions of people every year." With growing adoption and partnerships across flagship institutions, including UChicago Medicine, University Hospitals Cleveland, Northwestern, and Mayo Clinic, Ultromics is building regional clusters of clinical and commercial traction, particularly in high-prevalence regions like the Midwest. Its platform is helping hospitals reduce unnecessary tests, streamline workflows and initiate treatment earlier so it's more effective and less expensive. "Heart failure and cardiac amyloidosis impact millions of lives and strain healthcare systems, despite new approaches that have the potential to significantly improve patient outcomes. There is a critical need for scalable solutions that enable earlier, more accurate diagnosis and elevate the standard of care," said Umur Hursever, Partner at Lightrock. "Ultromics' AI-driven technology is already making a real-world impact, improving diagnostic accuracy, supporting clinical decisions, and expanding access to specialist care. The Lightrock team is delighted to support Ultromics' mission and growing impact." Ultromics has rapidly expanded its platform capabilities and U.S. market presence during the past year. In late 2024, the company received FDA Breakthrough Device clearance for EchoGo® Amyloidosis, followed in 2025 by the launch of EchoGo® Score, a new feature that adds AI-driven probability scoring to EchoGo® Heart Failure, helping clinicians detect HFpEF with greater nuance. These clinical advances are now supported by Medicare reimbursement for both outpatient and inpatient use, strengthening Ultromics' foundation for scaled adoption across U.S. hospitals. "There's a long-standing blind spot in cardiology where millions of patients with treatable heart failure are missed because their symptoms are subtle and echo images are hard to interpret," said Victor Westerlind, Managing Director at Allegis Capital. "What's exciting about Ultromics is how they're closing that gap. Their platform brings AI and cardiology together in a way that makes it easier for physicians to identify high-risk patients earlier. When paired with the latest treatment advances, it's a diagnostic win that will help save lives." About Ultromics Founded out of the University of Oxford, Ultromics is redefining cardiovascular care with FDA-cleared, AI-powered tools that enhance echocardiographic diagnosis. Built in partnership with the NHS and Mayo Clinic, its EchoGo® platform helps clinicians detect complex heart diseases earlier and more accurately—using nothing more than a standard ultrasound scan. Ultromics is backed by leading investors and U.S. healthcare systems and is on a mission to transform how heart disease is diagnosed and treated. For more, visit About Lightrock Lightrock is a global investment platform committed to building a sustainable future. Operating across private and public markets, Lightrock manages over $5.5 billion in assets and invests in Europe, North America, Latin America, Asia, and Africa. Lightrock is a certified B Corp with a dedicated team of over 130 professionals working across a network of six offices For more information, visit About L&G Established in 1836, L&G is one of the UK's leading financial services groups and a major global investor, with £1.1 trillion in total assets under management (as at FY24) of which c. 44% (c. £0.5 trillion) is international. We have a highly synergistic business model, which continues to drive strong returns. We are a leading player in Institutional Retirement, in Retail Savings and Protection, and in Asset Management through both public and private markets. Across the Group, we are committed to responsible investing and dedicated to serving the long-term savings and investment needs of customers and society. About Allegis Capital Allegis Capital is an early-stage venture capital firm partnering with companies that enable digital transformation across the enterprise. The firm supports founders with hands-on guidance, operational expertise, and access to a global network of industry leaders. With a long track record of building market-defining businesses, Allegis backs the teams and platforms reshaping how work gets done. Headquartered in Palo Alto, California, Allegis has been investing in enterprise innovation for over two decades. For more information, visit Photo - - View original content to download multimedia: SOURCE Ultromics Sign in to access your portfolio
